News | March 03, 2022
Merck KGaA reports higher profits on strong volumes across its businesses
Company expects strong organic growth in sales, EBITDA in 2022
Company expects strong organic growth in sales, EBITDA in 2022
Earlier today, the Foundation for the National Institutes of Health (FNIH) announced that Dr. Gerberding will become CEO of the FNIH on May 16
Adds to Merck’s growing global, multi-modality CDMO network, following newly formed CDMO business unit in Life Science
In the interim, Deepak Khanna will lead Human Health International.
Newly formed Life Science Services business unit to offer fully integrated CDMO and Contract Testing Services
KEYTRUDA is now approved as monotherapy for adults with Renal Cell Carcinoma (RCC)
Merck is studying the Complete Response Letter and it is not related to the safety of gefapixant
The tablet donations provided for the treatment of more than 600 million schoolchildren in affected countries in sub-Saharan Africa since 2007
Danny Bar-Zohar will become Global Head of R&D and Joern-Peter Halle will become Chief Strategy Officer
First Positive Study for KEYTRUDA in Adjuvant Stage IB-IIIA NSCLC
Subscribe To Our Newsletter & Stay Updated
